Brown University Health Pediatric Hematology/Oncology

Topics

• Hemoglobinopathies and Related Disorders 93
• Glioma Diagnosis and Treatment 60
• Childhood Cancer Survivors' Quality of Life 47
• Hematopoietic Stem Cell Transplantation 42
• Acute Lymphoblastic Leukemia research 32
• Neuroblastoma Research and Treatments 27
• Hemophilia Treatment and Research 24
• Acute Myeloid Leukemia Research 19
• Cancer Immunotherapy and Biomarkers 13
• Platelet Disorders and Treatments 12
• Lung Cancer Diagnosis and Treatment 11
• Lymphoma Diagnosis and Treatment 10

Most cited

1. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

   The New England journal of medicine · 2023 · 1,032 citations · Ayman Samkari

2. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

   The Lancet. Oncology · 2022 · 688 citations · Ayman Samkari

3. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.

   Lancet (London, England) · 2024 · 288 citations · Ayman Samkari

4. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.

   Nature medicine · 2024 · 168 citations · Peter Manley

5. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.

   The New England journal of medicine · 2021 · 348 citations · Leslie Lehmann

6. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.

   Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021 · 277 citations ·